Horizon Pharma’s Thyroid Eye Disease Treatment Could Become a Blockbuster, Analyst Predicts

Horizon Pharma’s late-stage treatment for active thyroid eye disease continues to demonstrate greater efficacy. Two months after releasing positive Phase III data, the company shared additional secondary endpoint data that shows higher levels of patient benefit.